Rezolute to Participate in Upcoming Investor Conferences

Core Insights - Rezolute, Inc. is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism [2] Group 1: Company Overview - Rezolute's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism and has demonstrated substantial benefits in clinical trials and real-world applications for congenital and tumor-related hyperinsulinism [2] Group 2: Upcoming Events - Management will participate in several investor conferences, including: - The Citizens JMP Life Sciences Conference on May 7-8, 2025 - H.C. Wainwright BioConnect Investor Conference on May 20, 2025 - Craig-Hallum Institutional Investor Conference on May 28, 2025 - Jefferies Global Healthcare Conference on June 3-5, 2025 - One-on-one investor meetings will be held throughout these conferences [1]